These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 16014176

  • 1. Variation in transcriptional regulation of cyclin dependent kinase inhibitor p21waf1/cip1 among human bronchogenic carcinomas.
    Harr MW, Graves TG, Crawford EL, Warner KA, Reed CA, Willey JC.
    Mol Cancer; 2005 Jul 13; 4():23. PubMed ID: 16014176
    [Abstract] [Full Text] [Related]

  • 2. Stable low-level expression of p21WAF1/CIP1 in A549 human bronchogenic carcinoma cell line-derived clones down-regulates E2F1 mRNA and restores cell proliferation control.
    Graves TG, Harr MW, Crawford EL, Willey JC.
    Mol Cancer; 2006 Jan 10; 5():1. PubMed ID: 16403226
    [Abstract] [Full Text] [Related]

  • 3. p53 inactivation upregulates p73 expression through E2F-1 mediated transcription.
    Tophkhane C, Yang SH, Jiang Y, Ma Z, Subramaniam D, Anant S, Yogosawa S, Sakai T, Liu WG, Edgerton S, Thor A, Yang X.
    PLoS One; 2012 Jan 10; 7(8):e43564. PubMed ID: 22952705
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Differential regulation of transcription and induction of programmed cell death by human p53-family members p63 and p73.
    Dietz S, Rother K, Bamberger C, Schmale H, Mössner J, Engeland K.
    FEBS Lett; 2002 Aug 14; 525(1-3):93-9. PubMed ID: 12163168
    [Abstract] [Full Text] [Related]

  • 7. Differential regulation of p73 variants in response to cisplatin treatment in SH-SY5Y neuroblastoma cells.
    Million K, Horvilleur E, Goldschneider D, Agina M, Raguénez G, Tournier F, Bénard J, Douc-Rasy S.
    Int J Oncol; 2006 Jul 14; 29(1):147-54. PubMed ID: 16773194
    [Abstract] [Full Text] [Related]

  • 8. Deregulated expression of E2F1 promotes proteolytic degradation of tumor suppressor p73 and inhibits its transcriptional activity.
    Ozaki T, Okoshi R, Ono S, Kubo N, Nakagawara A.
    Biochem Biophys Res Commun; 2009 Sep 11; 387(1):143-8. PubMed ID: 19576172
    [Abstract] [Full Text] [Related]

  • 9. [Effect of 14-3-3sigma on transcriptional activity of p73 gene].
    Sang MX, Geng CZ, Shan BE.
    Ai Zheng; 2007 May 11; 26(5):489-93. PubMed ID: 17672938
    [Abstract] [Full Text] [Related]

  • 10. Increased DeltaN-p73 expression in tumors by upregulation of the E2F1-regulated, TA-promoter-derived DeltaN'-p73 transcript.
    Pützer BM, Tuve S, Tannapfel A, Stiewe T.
    Cell Death Differ; 2003 May 11; 10(5):612-4. PubMed ID: 12728260
    [No Abstract] [Full Text] [Related]

  • 11. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM, Nugent JK, Zhao X, Irwin MS.
    Oncogene; 2008 Feb 07; 27(7):997-1003. PubMed ID: 17700533
    [Abstract] [Full Text] [Related]

  • 12. The gene expression index c-myc x E2F-1/p21 is highly predictive of malignant phenotype in human bronchial epithelial cells.
    DeMuth JP, Jackson CM, Weaver DA, Crawford EL, Durzinsky DS, Durham SJ, Zaher A, Phillips ER, Khuder SA, Willey JC.
    Am J Respir Cell Mol Biol; 1998 Jul 07; 19(1):18-24. PubMed ID: 9651176
    [Abstract] [Full Text] [Related]

  • 13. p73alpha expression induces both accumulation and activation of wt-p53 independent of the p73alpha transcriptional activity.
    Miro-Mur F, Meiller A, Haddada H, May E.
    Oncogene; 2003 Aug 21; 22(35):5451-6. PubMed ID: 12934105
    [Abstract] [Full Text] [Related]

  • 14. Yin Yang 1 induces transcriptional activity of p73 through cooperation with E2F1.
    Wu S, Murai S, Kataoka K, Miyagishi M.
    Biochem Biophys Res Commun; 2008 Jan 04; 365(1):75-81. PubMed ID: 17980704
    [Abstract] [Full Text] [Related]

  • 15. E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry.
    Alla V, Kowtharapu BS, Engelmann D, Emmrich S, Schmitz U, Steder M, Pützer BM.
    Cell Cycle; 2012 Aug 15; 11(16):3067-78. PubMed ID: 22871739
    [Abstract] [Full Text] [Related]

  • 16. Two new p73 splice variants, gamma and delta, with different transcriptional activity.
    De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M, Levrero M, Melino G.
    J Exp Med; 1998 Nov 02; 188(9):1763-8. PubMed ID: 9802988
    [Abstract] [Full Text] [Related]

  • 17. Kinase activity-independent suppression of p73alpha by AMP-activated kinase alpha (AMPKalpha).
    Lee YG, Lee SW, Sin HS, Kim EJ, Um SJ.
    Oncogene; 2009 Feb 19; 28(7):1040-52. PubMed ID: 19079340
    [Abstract] [Full Text] [Related]

  • 18. Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1).
    Kreis NN, Sommer K, Sanhaji M, Krämer A, Matthess Y, Kaufmann M, Strebhardt K, Yuan J.
    Cell Cycle; 2009 Feb 01; 8(3):460-72. PubMed ID: 19177004
    [Abstract] [Full Text] [Related]

  • 19. Regulation of telomerase activity by the p53 family member p73.
    Beitzinger M, Oswald C, Beinoraviciute-Kellner R, Stiewe T.
    Oncogene; 2006 Feb 09; 25(6):813-26. PubMed ID: 16205639
    [Abstract] [Full Text] [Related]

  • 20. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
    Malaguarnera R, Vella V, Pandini G, Sanfilippo M, Pezzino V, Vigneri R, Frasca F.
    Mol Cancer Res; 2008 Jan 09; 6(1):64-77. PubMed ID: 18234963
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.